🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣 Updated ESMO #ClinicalPracticeGuideline on #localised #rectalcancer: tailored intensification/de-intensification, complex radiological factors, #biomarkers & organ-preserving Tx options. #ESMOGuidelines 🔗 ow.ly/q2VV50VWTAU

#ESMOMembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/XX3W50VZQyL FabriceAndre

🆕article in press: Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial Jean-Yves Blay doi.org/10.1016/j.anno…

🆕article in press: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial tombal, silke gillessen, EORTC tinyurl.com/bdhhv78u

📢#ASCO25 concomitant publication: Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis Jean Hoffman-Censits tinyurl.com/ym4cwmvu

📢#ASCO25 concomitant publication: Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-Year median follow-up of the phase III EV-302/KEYNOTE- A39 trial Tom Powles tinyurl.com/3w4mz94s

📢#ASCO25 concomitant publication: Dostarlimab and niraparib in primary advanced ovarian cancer tinyurl.com/y29sfsw5

📢#ASCO25 concomitant publication: Savolitinib+osimertinib in EGFR-mutated advanced NSCLC with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study tinyurl.com/bdcwrfhd

📢#ASCO25 concomitant publication: Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses tinyurl.com/nf832d9b

📢#ASCO25 concomitant publication: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic HSPC: prevalence and impact on outcomes David Olmos David Lorente Ignacio González Ginel Nuria Romero C@silda Ll@cer Daniel Castellano Bernardo Herrera Imbroda tinyurl.com/yyd25nbc

🆕 article in press: Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision doi.org/10.1016/j.anno…

🆕article in press: Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer doi.org/10.1016/j.anno…

🆕Article of the Month podcast🎧Prof. Nick Turner The ICR discusses whole genome sequencing-powered ctDNA sequencing for breast cancer detection with Annals of Oncology Editor-in-Chief Tom Powles soundcloud.com/esmo-podcasts/… To read the article see: doi.org/10.1016/j.anno…

🆕 article in press: What is required to deliver practice changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study doi.org/10.1016/j.anno…

🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations annalsofoncology.org/article/S0923-…

🆕 article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases annalsofoncology.org/article/S0923-…

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… Mark Awad Biagio Ricciuti, MD, PhD

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines

🆕 Article in press: Health-Related Quality of life of patients with metastatic melanoma treated with tumor infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial annalsofoncology.org/article/S0923-…

🆕 Article in press: Efficacy and safety of biweekly single-dose actinomycin D vs multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial annalsofoncology.org/article/S0923-…